Andrea Acevedo1, Brian O Mullin2, Ana M Progovac2,3, Theodore L Caputi2, J Michael McWilliams4,5, Benjamin L Cook2,3. 1. Department of Community Health, Tufts University, Medford, Massachusetts, USA. 2. Health Equity Research Lab, Department of Psychiatry, Cambridge Health Alliance, Cambridge, Massachusetts, USA. 3. Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA. 5. Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To assess the impact of the Medicare Shared Savings Program (MSSP) ACOs on mental health and substance use services utilization and racial/ethnic disparities in care for these conditions. DATA SOURCES: Five percent random sample of Medicare claims from 2009 to 2016. STUDY DESIGN: We compared Medicare beneficiaries in MSSP ACOs to non-MSSP beneficiaries, stratifying analyses by Medicare eligibility (disability vs age 65+). We estimated difference-in-difference models of MSSP ACOs on mental health and substance use visits (outpatient and inpatient), medication fills, and adequate care for depression adjusting for age, sex, race/ethnicity, region, and chronic medical and behavioral health conditions. To examine the differential impact of MSSP on our outcomes by race/ethnicity, we used a difference-in-difference-in-differences (DDD) design. DATA COLLECTION/EXTRACTION METHODS: Not applicable. PRINCIPAL FINDINGS: MSSP ACOs were associated with small reductions in outpatient mental health (Coeff: -0.012, P < .001) and substance use (Coeff: -0.001, P < .01) visits in the disability population, and in adequate care for depression for both the disability- and age-eligible populations (Coeff: -0.028, P < .001; Coeff: -0.012, P < .001, respectively). MSSP ACO's were also associated with increases in psychotropic medications (Coeff: 0.007 and Coeff: 0.0213, for disability- and age-eligible populations, respectively, both P < .001) and reductions in inpatient mental health stays (Coeff:-0.004, P < .001, and Coeff:-0.0002, P < .01 for disability- and age-eligible populations, respectively) and substance use-related stays for disability-eligible populations (Coeff:-0.0005, P<.05). The MSSP effect on disparities varied depending on type of service. CONCLUSIONS: We found small reductions in outpatient and inpatient stays and in rates of adequate care for depression associated with MSSP ACOs. As MSSP ACOs are placed at more financial risk for population-based treatment, it will be important to include more robust behavioral health quality measures in their contracts and to monitor disparities in care.
OBJECTIVE: To assess the impact of the Medicare Shared Savings Program (MSSP) ACOs on mental health and substance use services utilization and racial/ethnic disparities in care for these conditions. DATA SOURCES: Five percent random sample of Medicare claims from 2009 to 2016. STUDY DESIGN: We compared Medicare beneficiaries in MSSP ACOs to non-MSSP beneficiaries, stratifying analyses by Medicare eligibility (disability vs age 65+). We estimated difference-in-difference models of MSSP ACOs on mental health and substance use visits (outpatient and inpatient), medication fills, and adequate care for depression adjusting for age, sex, race/ethnicity, region, and chronic medical and behavioral health conditions. To examine the differential impact of MSSP on our outcomes by race/ethnicity, we used a difference-in-difference-in-differences (DDD) design. DATA COLLECTION/EXTRACTION METHODS: Not applicable. PRINCIPAL FINDINGS: MSSP ACOs were associated with small reductions in outpatient mental health (Coeff: -0.012, P < .001) and substance use (Coeff: -0.001, P < .01) visits in the disability population, and in adequate care for depression for both the disability- and age-eligible populations (Coeff: -0.028, P < .001; Coeff: -0.012, P < .001, respectively). MSSP ACO's were also associated with increases in psychotropic medications (Coeff: 0.007 and Coeff: 0.0213, for disability- and age-eligible populations, respectively, both P < .001) and reductions in inpatient mental health stays (Coeff:-0.004, P < .001, and Coeff:-0.0002, P < .01 for disability- and age-eligible populations, respectively) and substance use-related stays for disability-eligible populations (Coeff:-0.0005, P<.05). The MSSP effect on disparities varied depending on type of service. CONCLUSIONS: We found small reductions in outpatient and inpatient stays and in rates of adequate care for depression associated with MSSP ACOs. As MSSP ACOs are placed at more financial risk for population-based treatment, it will be important to include more robust behavioral health quality measures in their contracts and to monitor disparities in care.
Authors: Tami L Mark; Katharine R Levit; Rita Vandivort-Warren; Jeffrey A Buck; Rosanna M Coffey Journal: Health Aff (Millwood) Date: 2011-02 Impact factor: 6.301
Authors: J Michael McWilliams; Laura A Hatfield; Bruce E Landon; Pasha Hamed; Michael E Chernew Journal: N Engl J Med Date: 2018-09-05 Impact factor: 91.245
Authors: Helen Newton; Susan H Busch; Mary F Brunette; Donovan T Maust; A James O'Malley; Ellen Meara Journal: Psychiatr Serv Date: 2022-04-05 Impact factor: 4.157
Authors: Andrea Acevedo; Brian O Mullin; Ana M Progovac; Theodore L Caputi; J Michael McWilliams; Benjamin L Cook Journal: Health Serv Res Date: 2021-02-05 Impact factor: 3.734